RTG-loaded nanomicelles (CS–VES–NAC) for oral anti-HIV drug delivery

Chitin and chitosan: Properties and applications

Rinaudo, M. (2006) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2006.06.001 · Cited by 8,378 · see citing works

Polymer Vesicles

Discher, D., & Eisenberg, A. (2002) · Science · doi:10.1126/science.1074972 · Cited by 2,251 · see citing works

Chitosan and its derivatives for tissue engineering applications

Kim, I.-Y., Seo, S.-J., Moon, H., Yoo, M. K., Park, I.-Y., Kim, B.-C., & Cho, C.-S. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.07.009 · Cited by 1,430 · see citing works

Inhaling medicines: delivering drugs to the body through the lungs

Patton, J. S., & Byron, P. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2153 · Cited by 1,329 · see citing works

Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery

Nishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052 · see citing works

Oral drug absorption enhancement by chitosan and its derivatives

Thanou, M., Verhoef, J. C., & Junginger, H. E. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00231-9 · Cited by 689 · see citing works

Development of the polymer micelle carrier system for doxorubicin

Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · see citing works

Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation

Wang, W., Bo, S., Li, S., et al. (1991) · International Journal of Biological Macromolecules · doi:10.1016/0141-8130(91)90027-r · Cited by 541 · see citing works

Oral Delivery of Peptide Drugs

Hamman, J. H., Enslin, G. M., & Kotz, A. F. (2005) · BioDrugs · doi:10.2165/00063030-200519030-00003 · Cited by 504 · see citing works

Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: An attractive tool for drug delivery

Rijcken, C. J. F., Soga, O., Hennink, W. E., & van Nostrum, C. F. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.023 · Cited by 487 · see citing works

Non-viral gene therapy: polycation-mediated DNA delivery

Thomas, M., & Klibanov, A. M. (2003) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1321-8 · Cited by 482 · see citing works

Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance

Lee, E. S., Gao, Z., Kim, D., Park, K., Kwon, I. C., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.024 · Cited by 400 · see citing works

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389 · see citing works

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

Raffi, F., Jaeger, H., Quirós-Roldán, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C. A., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 378 · see citing works

XVI International AIDS Conference

Das, P. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70593-x · Cited by 244 · see citing works

Advances in chitosan-based drug delivery vehicles

Hu, L., Sun, Y., & Wu, Y. F. (2013) · Nanoscale · doi:10.1039/c3nr00338h · Cited by 243 · see citing works

Therapeutic potential of nanoparticulate systems for macrophage targeting

Chellat, F., Merhi, Y., Moreau, A., & Yahia, L. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.044 · Cited by 237 · see citing works

Controlled Pulmonary Drug Delivery

Smyth, H. D. C., & Hickey, A. J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9745-6 · Cited by 231 · see citing works

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

Blanco, J. L., Varghese, V., Rhee, S., Gatell, J. M., & Shafer, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir025 · Cited by 218 · see citing works

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

Iwamoto, M., Wenning, L., Petry, A., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100281 · Cited by 170 · see citing works

N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates

Katō, Y., Onishi, H., & Machida, Y. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00598-2 · Cited by 168 · see citing works

Zwitterionic Chitosan Derivatives for pH-Sensitive Stealth Coating

Xu, P., Bajaj, G., Shugg, T., et al. (2010) · Biomacromolecules · doi:10.1021/bm100481r · Cited by 106 · see citing works

Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine

Xu, P., Quick, G. K., & Yeo, Y. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.012 · Cited by 93 · see citing works

Long-Circulating 15 nm Micelles Based on Amphiphilic 3-Helix Peptide–PEG Conjugates

Dong, H., Dube, N., Shu, J. Y., Seo, J. W., Mahakian, L. M., Ferrara, K. W., & Xu, T. (2012) · ACS Nano · doi:10.1021/nn301142r · Cited by 92 · see citing works

Preparation of partially N-succinylated chitosans and their cross-linked gels

Yamaguchi, R., Arai, Y., Itoh, T., et al. (1981) · Carbohydrate Research · doi:10.1016/s0008-6215(00)84614-5 · Cited by 92 · see citing works

New Design of Helix Bundle Peptide−Polymer Conjugates

Shu, J. Y., Tan, C., DeGrado, W. F., et al. (2008) · Biomacromolecules · doi:10.1021/bm800113g · Cited by 89 · see citing works

Drug Targeting by Surface Cationization

Blau, S., Jubeh, T. T., Haupt, S. M., & Rubinstein, A. (2000) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v17.i5.10 · Cited by 84 · see citing works

Cytotoxicity, metabolism and cellular uptake of the mycotoxin deoxynivalenol in human proximal tubule cells and lung fibroblasts in primary culture

Königs, M., Lenczyk, M., Schwerdt, G., Holzinger, H., Gekle, M., & Humpf, H. (2007) · Toxicology · doi:10.1016/j.tox.2007.07.016 · Cited by 73 · see citing works

Biodisposition Characteristics of N-Succinyl-chitosan and Glycol-chitosan in Normal and Tumor-bearing Mice.

KAMIYAMA, K., Onishi, H., & Machida, Y. (1999) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.22.179 · Cited by 68 · see citing works

Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate.

Yang, L., Chen, L.-Q., Zeng, R., Li, C., Qiao, R., Hu, L.-M., & Li, Z.-L. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.013 · Cited by 67 · see citing works

Severe rhabdomyolysis associated with raltegravir use

Zembower, T., Gerzenshtein, L., Coleman, K., et al. (2008) · AIDS · doi:10.1097/qad.0b013e328303be40 · Cited by 60 · see citing works

Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors

Laufer, R., Paz, O. G., DiMarco, A., Bonelli, F., Monteagudo, E., Summa, V., & Rowley, M. (2009) · Drug Metabolism And Disposition · doi:10.1124/dmd.108.023804 · Cited by 35 · see citing works

Biological Fate of Highly-Succinylated N-Succinyl-chitosan and Antitumor Characteristics of Its Water-soluble Conjugate with Mitomycin C at I.v. and I.p. Administration into Tumor-Bearing Mice.

Katō, Y., Onishi, H., & Machida, Y. (2000) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.23.1497 · Cited by 30 · see citing works

Increased Bioavailability of Rifampicin from Stimuli-Responsive Smart Nano Carrier

Mane, S. R., Dinda, H., Sathyan, A., et al. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am504402b · Cited by 24 · see citing works

Novel synthesis and in vitro drug release of polymeric prodrug: Chitosan–O-isopropyl-5′-O-d4T monophosphate conjugate

Yang, L., Zeng, R., Li, C., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.044 · Cited by 21 · see citing works

Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors

Wang, Y., Rong, J., Zhang, B., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.059 · Cited by 15 · see citing works

Effect of bond linkage on in vitro drug release and anti-HIV activity of chitosan-stavudine conjugates

Zeng, R., Wang, Z., Wang, H., et al. (2012) · Macromolecular Research · doi:10.1007/s13233-012-0022-5 · Cited by 14 · see citing works

Enhanced paracellular and transcellular paclitaxel permeation by chitosan–vitamin E succinate–N-acetyl-l-cysteine copolymer on Caco-2 cell monolayer

Lian, H., Zhang, T., Sun, J., et al. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2355-9 · Cited by 11 · see citing works

Recent Advances in Nanomicelles Delivery Systems.

Tawfik, S. M., Azizov, S., Elmasry, M. R., Sharipov, M., & Lee, Y.-I. (2020) · Nanomaterials · doi:10.3390/nano11010070 · Cited by 156 · see citing works

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

Yilmaz, A., Gisslén, M., Spudich, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006877 · Cited by 86 · see citing works

Phenotypic susceptibility of HIV-2 to raltegravir

Smith, R. A., Raugi, D. N., Kiviat, N. B., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834d8e52 · Cited by 26 · see citing works

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Chirch (2010) · Infection and Drug Resistance · doi:10.2147/idr.s9689 · Cited by 1 · see citing works

Role of raltegravir in the management of HIV-1 infection

Hicks, C. B., & Okeke (2011) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s13985 · Cited by 9 · see citing works

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration

Mello, A. F., Buclin, T., Franc, C., Colombo, S. F., Cruchon, S., Guignard, N., Biollaz, J., Telenti, A., Decosterd, L. A., & Cavassini, M. L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr151 · Cited by 26 · see citing works